Back to top
more

Personalis (PSNL)

(Delayed Data from NSDQ)

$1.30 USD

1.30
162,172

-0.08 (-5.80%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $1.30 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (162 out of 252)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Bausch Health (BHC) Surpasses Q4 Earnings and Revenue Estimates

Bausch (BHC) delivered earnings and revenue surprises of 13.86% and 7.15%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of 10.71% and 0.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of 1.61% and 8.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Personalis (PSNL) Upgraded to Buy: Here's What You Should Know

Personalis (PSNL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Personalis (PSNL) Reports Q3 Loss, Misses Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of 7.94% and 5.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of 4.76% and 21.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of -10.53% and 2.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Personalis (PSNL) Reports Q4 Loss, Lags Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of 11.76% and 0.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Personalis (PSNL) Q4 Earnings Expected to Decline

Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of 0.00% and 0.28%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Personalis (PSNL) to Report a Decline in Earnings: What to Look Out for

Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of 12.82% and 2.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Personalis (PSNL) Q2 Earnings Expected to Decline

Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of 21.62% and 2.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Personalis (PSNL) Q1 Earnings Expected to Decline

Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Personalis (PSNL) Stock Jumps 7.9%: Will It Continue to Soar?

Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

What's in Store for Zomedica (ZOM)This Earnings Season?

Zomedica (ZOM) may provide an update on Truforma commercialization progress when it reports fourth-quarter 2020 results.

What's in Store for Mallinckrodt (MNKKQ)This Earnings Season?

Negative impact of COVID-19 is likely to have hurt sales of Mallinckrodt (MNKKQ) during the fourth quarter. Investors are likely to focus on bankruptcy proceedings during the earning call.

Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of 10.00% and 2.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Personalis (PSNL) to Report a Decline in Earnings: What to Look Out for

Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Personalis (PSNL) Looks Good: Stock Adds 8% in Session

Personalis (PSNL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of 14.71% and 14.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FDA Advisory Committee Recommends Mallinckrodt's Trelipressin

The Cardiovascular and Renal Drugs Advisory Committee of the FDA votes in favor of Mallinckrodt's (MNK) investigational agent, terlipressin, to treat adults with hepatorenal syndrome type 1.

Personalis, Inc. (PSNL) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Personalis, Inc. (PSNL).